Now I have enough calibration data. Let me finalize the review.

**Round 1 bracket**: 5.5–7.0 (clearly above the weak anchors at 3–5.5, comparable to solid accept-tier papers)

**Round 2 narrowing**: Comparing against QG31By6S6w (Malenia, 6.25), HNOo4UNPBF (Scale-Aware Anomaly Detection, 6.50), and LjeqMvQpen (Transformer Fusion OT, 6.50), the paper is comparable in methodology completeness and empirical rigor. It achieves SOTA on two benchmarks and has comprehensive ablation, but the missing proposal verification and backbone baseline are more significant gaps than those anchors had. I'd place it at **6.5**.

## Summary
This paper proposes an end-to-end multi-view diabetic retinopathy (DR) grading framework with two modules: GALP (Grade-Activated Lesion Proposal), which generates lesion proposals on-the-fly from stage-wise auxiliary classifiers via CAM-derived grade-conditioned evidence maps, and LGRF (Cross-View Lesion Expert Guided Regional Fusion), which uses MoE-based routing and Top-K weighted cross-view attention to fuse lesion proposals across views. Evaluated on MFIDDR (4-view) and DRTiD (2-view) datasets, the method achieves 83.9% accuracy without external annotations—matching or surpassing several externally-informed baselines—and 84.6% with lesion masks, establishing new SOTA on MFIDDR.

## Strengths
- **Strong empirical results without external annotations**: The lesion-free variant achieves 83.9% accuracy on MFIDDR (Table 1), surpassing all end-to-end baselines (best prior: ETMC at 81.5%) and matching or exceeding several methods requiring external annotations (CVSA with vessel: 82.6%, LFMVDR with lesion: 82.2%). On DRTiD, the method achieves 76.0% accuracy, outperforming CrossFIT (75.6%) and CVSA (74.7%) which use external information (Table 3).
- **Comprehensive ablation validates each component**: Removing GALP, Experts, or LGRF individually causes 1.2–1.6% accuracy drops (Table 4), confirming complementary contributions. Hyperparameter sensitivity analysis (Figure 3) over retention ratio, number of routed experts, and total experts demonstrates robust design choices and identifies clear operating points (α=0.5, K₂=2, M=6).
- **Dual-mode flexibility**: The framework optionally integrates external lesion annotations via SPADE, improving from 83.9% to 84.6% (Table 1), establishing new SOTA. This makes the method practically useful in both resource-constrained and resource-rich clinical settings.
- **Well-specified, reproducible method**: Equations 1–20 provide clear mathematical formulations for GALP's proposal generation, LGRF's expert routing, cross-view attention, and the combined training objective. Architecture details (patch sizes, expert counts, loss weights) are explicitly stated.

## Weaknesses

### Fatal
None

### Major
- **No verification that proposals correspond to actual lesions**: The paper's central thesis is that self-generated GALP proposals can substitute for expert lesion annotations. However, the paper provides no evidence that proposals actually identify lesion regions — no overlay visualizations on fundus images, no comparison against MFIDDR's available lesion segmentation masks (line 185: "the provider also releases lesion segmentation masks"), and no proposal-level precision/recall analysis. Without this, the 83.9% result could be driven entirely by the auxiliary supervision effect (forcing intermediate features to be grade-discriminative) rather than by meaningful lesion localization. This is the paper's most significant gap: the core claim about "reducing annotation needs" via self-derived lesion proposals is not directly substantiated by the evidence presented.

- **Missing backbone-matched control baseline**: The paper uses Swin-B (line 208), while most end-to-end baselines use weaker architectures: MVCNN.R uses ResNet50, MVCNN.V uses VGG19 (line 257). The headline claim of surpassing all end-to-end baselines therefore conflates backbone strength with module contribution. The closest Swin-B anchor is CVSA (82.6% with vessel annotations), making the 1.3% gap more meaningful, but a simple Swin-B + GAP + concatenation + linear classifier row in Table 1 is the natural control. The ablation rows (Table 4: "w/o LGRF" at 82.3%, "w/o GALP" at 82.7%) each still use partial proposed components rather than this clean baseline, leaving the backbone-vs-module attribution unclear.

### Minor
- **No variance or statistical significance reporting**: All results are single-point numbers with no confidence intervals or standard deviations across runs. Given that margins between methods are often 1–2% (e.g., 83.9% vs. 84.2% for WGLIN), and ablation differences are ~1%, run-to-run variance could meaningfully affect interpretation. This is common in the field but worth addressing.

- **No limitations discussion**: The paper does not acknowledge limitations. The method's reliance on CAM-based proposals (which can highlight grade-correlated but clinically irrelevant regions like optic disc or image borders) and sensitivity to the retention ratio α (Figure 3a shows 1.7% accuracy swing between α=0.2 and α=0.5) deserve honest discussion.

### Trivial
- **No computational cost analysis**: The MoE routing with M=6 experts across 4 stages for N views introduces non-trivial parameter and compute overhead. A brief comparison of FLOPs or inference time would aid practical assessment.

## Nice-to-Haves
- Report FLOPs/parameter counts vs. baselines to contextualize the architectural overhead of the MoE and GALP modules.
- A brief limitations section acknowledging CAM's potential to highlight non-lesion grade-correlated regions.

## Removed Points
These points are flagged to be removed, treat them with caution.
- "DRTiD results lack 'with lesion' comparison" — This is scope creep. The paper's focus is annotation-free grading; DRTiD's externally-informed baselines (CrossFIT with OD/macula coordinates) are already compared. The absence of a lesion-augmented variant on DRTiD is not a gap in the paper's stated contribution.
- Formatting/typo nitpicks — parser artifacts, not author issues.

## Novel Insights
Beyond the paper's own contributions, the comparative analysis reveals an interesting tension: the paper's strongest empirical contribution may actually be the auxiliary supervision effect of GALP's multi-stage classifiers rather than the lesion localization per se. The ablation shows GALP contributes 1.2% even when its proposals are not used for targeted fusion (w/o LGRF: 82.3% still uses GALP-generated proposals with concatenation), suggesting the auxiliary classification loss itself is a significant driver. If the authors can verify that proposals align with lesions, the contribution is substantially more novel; if not, the paper's value shifts from "annotation-free lesion detection" to "auxiliary-supervised multi-view fusion," which is still useful but less distinctive.

## Suggestions
- Add a qualitative figure (even 5–10 examples) overlaying GALP proposals on fundus images, optionally compared against MFIDDR's available lesion segmentation masks. This single addition would most directly validate or reframe the core claim.
- Add a Swin-B + GAP + concatenation + linear classifier row to Table 1 to cleanly isolate module contribution from backbone strength.
- Run the main method and key ablation variants with 3–5 random seeds to report mean ± std, given the small margins between methods.

## Calibration Anchors

| Round | Path | Avg Score | Comparison |
|-------|------|-----------|------------|
| 1 | EjIKerYk1O (aircraft distance) | 2.33 | Much weaker; different domain, limited evaluation |
| 1 | SNNdmfqWFu (SpecRaGE) | 3.40 | Weaker; limited generalization, scalability issues |
| 1 | MqvQUP7ZuZ (DC3DO) | 3.00 | Weaker; limited comparison |
| 1 | Lv9KZ5qCSG (Eye Fairness) | 5.50 | Comparable domain (eye imaging); dataset contribution, weaker method evaluation |
| 1 | ZBH4fqQwJQ (Multi-view diffusion) | 4.75 | Weaker; limited novelty |
| 1 | FUgrjq2pbB (MVDream) | 6.50 | Stronger; more novel and impactful contribution |
| 1 | QQBPWtvtcn (LVSM) | 7.67 | Stronger; more novel architecture |
| 1 | P4o9akekdf (NoPoSplat) | 8.00 | Much stronger; highly novel |
| 2 | NJxCpMt0sf (M4oE) | 5.75 | Comparable; medical MoE, weaker evaluation |
| 2 | M3kBtqpys5 (TEF multi-view) | 6.25 | Comparable; multi-view classification, similar rigor |
| 2 | QG31By6S6w (Malenia) | 6.25 | Comparable; medical lesion segmentation, similar novelty |
| 2 | HNOo4UNPBF (Scale-Aware) | 6.50 | Comparable; medical anomaly detection, SOTA results but incremental |
| 2 | IwgmgidYPS (MedTrinity) | 6.00 | Weaker contribution type (dataset), comparable evaluation |
| 2 | yVJd8lKyVX (HSQ) | 6.00 | Comparable; MoE for classification, similar novelty |
| 2 | VOVFvaxgD0 (MoH) | 5.75 | Weaker; rejected, incremental attention modification |
| 2 | LjeqMvQpen (Transformer Fusion OT) | 6.50 | Comparable; novel fusion, strong evaluation |
| 2 | rawj2PdHBq (Synthetic MedVLP) | 6.00 | Mixed reviews; interesting question but weaker results |
| 2 | 7WUdjDhF38 (RPE) | 4.50 | Weaker; limited novelty |
| 2 | gJTPyCZmbj (PagFormer) | 4.25 | Weaker; limited baselines |
| 2 | Wnu2c6pjs1 (RadEyeVideo) | 5.25 | Weaker; limited evaluation |
| 2 | t1J2CnDFwj (Multi-View Classification) | 5.75 | Comparable; multi-view classification |
| 2 | pdJXYfJjz9 (CoIC deraining) | 6.20 | Comparable; image processing, similar rigor |
| 2 | r92RVhnzKy (Regformer) | 6.75 | Comparable; image processing, strong results |

**Round-1 bracket**: 5.5–7.0. The paper is clearly above the weak anchors (3–5.5) and below the strong anchors (7.5+). 

**Round-2 narrowing**: Comparing against the 6.0–6.50 anchors (M4oE at 5.75, TEF at 6.25, Malenia at 6.25, Scale-Aware at 6.50, Transformer Fusion OT at 6.50), the paper has stronger empirical results (new SOTA on two benchmarks) and better methodological specification than most. However, the missing proposal verification and backbone baseline are more significant gaps than those anchors typically had. The paper sits slightly above the 6.25 anchors due to its strong empirical results, but the core narrative gap prevents it from reaching the 6.75–7.0 range.

**Final score**: 6.5 — a solid, above-average paper with strong empirical contributions and a well-designed method, but held back by two significant evidentiary gaps (proposal verification and backbone baseline) that prevent full confidence in its central claims.

MY FINAL SCORE: <score>6.5</score>
MY FINAL DECISION: <decision>Accept</decision>